143 related articles for article (PubMed ID: 27019158)
1. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
Wu J; Gießmann T; Lang B; Elgadi M; Huang F
J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
[TBL] [Abstract][Full Text] [Related]
2. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Adkison KK; Jones LS; Lou Y; Gan J; Wilfret DA
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):338-45. PubMed ID: 27129005
[TBL] [Abstract][Full Text] [Related]
3. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Sabo JP; Lang B; Elgadi M; Huang F
Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
[TBL] [Abstract][Full Text] [Related]
4. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
5. Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.
Lindsay J; Mudge S; Thompson GR
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297369
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study.
Huang F; Voelk C; Trampisch M; Rowland L; Schultz A; Sabo JP
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):84-93. PubMed ID: 29427400
[TBL] [Abstract][Full Text] [Related]
7. Effect of Steady-State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open-Label, Fixed-Sequence Crossover Study.
Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Quinson AM; Haertter S
J Clin Pharmacol; 2017 Oct; 57(10):1305-1314. PubMed ID: 28513969
[TBL] [Abstract][Full Text] [Related]
8. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
[TBL] [Abstract][Full Text] [Related]
9. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
[TBL] [Abstract][Full Text] [Related]
10. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
Manns MP; Bourlière M; Benhamou Y; Pol S; Bonacini M; Trepo C; Wright D; Berg T; Calleja JL; White PW; Stern JO; Steinmann G; Yong CL; Kukolj G; Scherer J; Boecher WO
J Hepatol; 2011 Jun; 54(6):1114-22. PubMed ID: 21145839
[TBL] [Abstract][Full Text] [Related]
11. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.
Joseph D; Rose P; Strelkowa N; Schultz A; Garcia J; Elgadi M; Huang F
J Clin Pharmacol; 2015 Apr; 55(4):384-91. PubMed ID: 25352040
[TBL] [Abstract][Full Text] [Related]
12. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.
Li L; Xiang YX; Yang GP; Zhang XF; Yang XY; Yang S; Huang J
Invest New Drugs; 2021 Jun; 39(3):796-802. PubMed ID: 33420642
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Sikes C; Stark JG; McMahen R; Engelking D
Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
[TBL] [Abstract][Full Text] [Related]
16. Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects.
Chen LZ; Rose P; Mao Y; Yong CL; St George R; Huang F; Latli B; Mandarino D; Li Y
Antimicrob Agents Chemother; 2014; 58(4):2369-76. PubMed ID: 24514093
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Wilfret DA; Walker J; Voitenleitner C; Baptiste-Brown S; Lovern M; Kim J; Adkison K; Shotwell B; Mathis A; Moss L; Lee D; Yu L; Gan J; Spaltenstein A
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):439-48. PubMed ID: 27129119
[TBL] [Abstract][Full Text] [Related]
18. Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Zeuzem S; Mantry P; Soriano V; Buynak RJ; Dufour JF; Pockros PJ; Wright D; Angus P; Buti M; Stern JO; Kadus W; Vinisko R; Böcher W; Mensa FJ
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):923-6. PubMed ID: 27140229
[TBL] [Abstract][Full Text] [Related]
19. Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
Katsube T; Wajima T; Fukuhara T; Kano T
Clin Ther; 2019 Sep; 41(9):1747-1754.e2. PubMed ID: 31303281
[TBL] [Abstract][Full Text] [Related]
20. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
